

[Skip to main content](#)

Dexamethasone Sodium Phosphate Injection, USP (Hexadrol)

??? ??????: 30 ?????2/?????? 2017

Fluid and electrolyte disturbances

- Sodium retention
- Fluid retention
- Congestive heart failure in susceptible patients
- Potassium loss
- Hypokalemic alkalosis
- Hypertension

Musculoskeletal

- Muscle weakness
- Steroid myopathy
- Loss of muscle mass
- Osteoporosis
- Vertebral compression fractures
- Aseptic necrosis of femoral and humeral heads
- Pathologic fracture of long bones

Gastrointestinal

- Peptic ulcer with possible subsequent perforation and hemorrhage
- Pancreatitis
- Abdominal distention
- Ulcerative esophagitis

Dermatological

- Impaired wound healing
- Thin fragile skin
- Facial erythema
- Increased sweating
- May suppress reactions to skin tests
- Petechiae and ecchymoses

Neurological

- Convulsions
- Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment
- Vertigo
- Headache

Ophthalmic

- Posterior subcapsular cataracts
- Increased intraocular pressure
- Glaucoma

Endocrine

Menstrual irregularities
Development of cushingoid state
Suppression of growth in children
Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness
Decreased carbohydrate tolerance
Manifestations of latent diabetes mellitus
Increased requirements for insulin or oral hypoglycemic agents in diabetics

Metabolic

Negative nitrogen balance due to protein catabolism

Miscellaneous

Hyperpigmentation or hypopigmentation
Subcutaneous and cutaneous atrophy
Sterile abscess
Postinjection flare, following intra-articular use
Charcot-like arthropathy
Itching, burning, tingling in the ano-genital region